Cargando…

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

BACKGROUND: As a prelude to combination studies aimed at resistance reversal, this dose-escalation/dose-expansion study investigated the selective Src kinase inhibitor saracatinib (AZD0530) in combination with carboplatin and/or paclitaxel. METHODS: Patients with advanced solid tumours received sara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaye, S, Aamdal, S, Jones, R, Freyer, G, Pujade-Lauraine, E, de Vries, E G E, Barriuso, J, Sandhu, S, Tan, D S-W, Hartog, V, Kuenen, B, Ruijter, R, Kristensen, G B, Nyakas, M, Barrett, S, Burke, W, Pietersma, D, Stuart, M, Emeribe, U, Boven, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364128/ https://www.ncbi.nlm.nih.gov/pubmed/22531637 http://dx.doi.org/10.1038/bjc.2012.158

Ejemplares similares

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
por: McGivern, Niamh, et al.
Publicado: (2017)

Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
por: Vasanthi, Suraj S., et al.
Publicado: (2023)

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
por: Nygaard, Haakon B, et al.
Publicado: (2015)

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
por: Baird, Kristin, et al.
Publicado: (2020)

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023)

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
por: Huang, R Y-J, et al.
Publicado: (2013)

Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy
por: Sharma, Shaunik, et al.
Publicado: (2021)

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial
por: van Dyck, Christopher H., et al.
Publicado: (2019)

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
por: Gwanmesia, Patricia Mambou, et al.
Publicado: (2009)

AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling
por: Zhao, Yi, et al.
Publicado: (2017)

Synergistic effect of STAT3-targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo
por: Liu, Qingjun, et al.
Publicado: (2019)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
por: Williams, Eleanor, et al.
Publicado: (2021)

Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro
por: Shin, Jin Soo, et al.
Publicado: (2018)

Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
por: Thompson, Summer L., et al.
Publicado: (2021)

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
por: González Martín, Antonio, et al.
Publicado: (2019)

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines
por: Nakachi, I, et al.
Publicado: (2016)

Gut dysbiosis following organophosphate, diisopropylfluorophosphate (DFP), intoxication and saracatinib oral administration
por: Gage, Meghan, et al.
Publicado: (2022)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma
por: Heusschen, Roy, et al.
Publicado: (2016)

Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice
por: Luo, Xin-Ming, et al.
Publicado: (2021)

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
por: Wagner, U, et al.
Publicado: (2012)

Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
por: Korst, A. E., et al.
Publicado: (1997)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
por: Lang, Liwei, et al.
Publicado: (2018)

Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
por: Liao, Xia, et al.
Publicado: (2020)

Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
por: Du, Guifang, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain
por: Danson, Sarah, et al.
Publicado: (2019)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
por: Yap, Timothy A., et al.
Publicado: (2021)

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
por: Sioud, Mouldy, et al.
Publicado: (2016)

P05.30. Integrating complementary and alternative medicine into mainstream health care: an empirical study of seven health care services in Australia
por: Singer, J, et al.
Publicado: (2012)

Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts
por: Harrach, Saliha, et al.
Publicado: (2017)

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin
por: Dellavedova, Giulia, et al.
Publicado: (2023)

How nephrotoxic is carboplatin?
por: Hardy, J. R., et al.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_ms1mtjcm1gsvspi2mkphvf8h0j